Losartan treating podocyte injury induced by Ang II via downregulation of TRPC6 in podocytes.

Abstract

OBJECTIVE:

In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan.

METHODS:

This study set up three groups: a control group; an Ang II group (Ang II 10(-6) mol/l, Sigma); and a losartan group (losartan 10(-6) mol/l, Sigma). We used RT-PCR assay to detect TRPC6 mRNA expression, and Western blot to detect TRPC6 protein expression.

RESULTS:

TRPC6 overexpression was the basic change of podocyte injury and proteinuria occurrence. Losartan can treat podocyte injury and proteinuria induced by Ang II via downregulation of TRPC6 in podocytes.

CONCLUSION:

These findings maybe provide an ideal drug target for the diagnosis and treatment of acquired glomerular diseases.

• Authors: Chi-Xianggeng, Hu-Bo, S Y Yu, Yin-Lianghong, Meng-Yu, Wang-Boxun, Yang-Jinsheng, Lin-Jiahui, Huang-Dexu, Chen-Lanlan
• Journal: Journal of the renin-angiotensin-aldosterone system : JRAAS (J Renin Angiotensin Aldosterone Syst) Vol. 16 Issue 4 Pg. 1118-24 (Dec 2015) ISSN: 1752-8976 [Electronic] England
• PMID: 25795457 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2015.

Chemical References

• RNA, Messenger
• TRPC Cation Channels
• Angiotensin II
• Losartan

Topics

• Angiotensin II (adverse effects)
• Animals
• Blotting, Western
• Down-Regulation (drug effects)
• Losartan (pharmacology, therapeutic use)
• Mice
• Podocytes (drug effects, pathology)
• RNA, Messenger (genetics, metabolism)
• TRPC Cation Channels (genetics, metabolism)
• Time Factors